Does hormone replacement therapy affect disease activity in patients with systemic lupus erythematosus?
Ramsey-Goldman
Rosalind
R
Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA. rgramsey@northwestern.edu
D015415:Biomarkers / Q000097:blood; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004967:Estrogens / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy*; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008593:Menopause; D012720:Severity of Illness Index; D016896:Treatment Outcome
D015415:Biomarkers; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone